News | February 24, 2026
Angelini Pharma and Quiver Bioscience team up to tackle genetic epilepsies
Under the deal, Quiver will receive an undisclosed advance payment and research support
Under the deal, Quiver will receive an undisclosed advance payment and research support
Dr Adams’ lab recently uncovered a novel cellular detoxification pathway driving Cisplatin resistance in NSCLC
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements
Patients with BRCA mutations often face aggressive disease and poor prognosis
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
Topline results from the Phase 2 VISTA trial show that PIPE-307 did not meet its primary or secondary efficacy endpoints
Adding one year of Imfinzi treatment to Bacillus Calmette-Guérin (BCG) induction and maintenance therapy delivered an early and sustained disease-free survival benefit vs. BCG alone
Contera Pharma will receive an upfront payment and full research funding for each target under investigation
Subscribe To Our Newsletter & Stay Updated
